

**Oklahoma Health Care Authority
Drug Utilization Review Board**

(DUR Board)

Meeting – July 10, 2013 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. June 12, 2013 DUR Minutes – Vote
 - B. June 13, 2013 DUR Recommendation Memorandum

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Medication Coverage Activity for June 2013
 - B. Pharmacy Help Desk Activity for June 2013
 - C. Retrospective Drug Evaluation: Focusing on Safety

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

5. **Action Item – Vote to Prior Authorize Oxtellar XR™ and Sabril® – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

6. **Action Item – Vote to Prior Authorize Aubagio® and Tecfidera™ – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Moore, Dr. Egesdal, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of Topical Corticosteroids – See Appendix E.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Updates
 - E. COP Recommendations
 - F. Utilization Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

8. **30 Day Notice to Prior Authorize Fulyzaq™ – See Appendix F.**
- A. Introduction
 - B. Product Summary
 - C. COP Recommendations
 - D. Product Details

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman

9. **30 Day Notice to Prior Authorize Vecamyl™ – See Appendix G.**
- A. Product Summary
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

10. **Action Item – Opioid Prescribing Initiative for Appropriate Treatment & Education – See Appendix H.**
- A. Survey Responses
 - B. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

11. **Presentation of Singulair® PA in the SoonerCare Population – Slides Only**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman

12. **Action Item – Annual Review of Uloric® and Colcrys® – See Appendix I.**
- A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

13. **FDA and DEA Updates – See Appendix J.**

14. **Future Business**

- A. Annual Reviews
- B. New Product Reviews

15. **Adjournment**